The care of patients with chronic hepatitis C infection (CHC) is rapidly changing. Increasing numbers of effective treatments for chronic hepatitis C virus (HCV) infection are available and additional drugs in late clinical development have the potential to significantly alter current treatment paradigms. If clinicians are aware of the availability of new therapies and understand how to appropriately use them, they provide unprecedented opportunities to treat CHC and reduce the risk of morbidity and mortality from the consequences of untreated CHC. However, many clinicians find it difficult to keep abreast of important developments in CHC therapeutics and other areas involved with the management of CHC patients, which can lead to suboptimal patient care.
We invite you to attend our live satellite symposium entitled, "The Evolving Landscape of HCV Treatment: Individualizing Care to Maximize SVR." This symposium will utilize patient case vignettes that describe the latest clinical information in this field and illustrate how to apply recent clinical findings to individual patients with CHC. Topics covered will include new treatment options for different HCV genotypes and difficult to treat populations, including those with various degrees of cirrhosis and chronic kidney disease. The outcome of this program will be that clinicians who treat patients with CHC will have an improved understanding of the various data supporting the optimal management of patients with CHC and will be able to apply this information in their clinical practices to improve patient care.
We look forward to your participation,
Nezam Afdhal, MD and Mark Sulkowski, MD
Program Co-Chairs
This activity has been designed to meet the educational needs of physicians, physician assistants, advanced practice nurses and other health care professionals involved in the care of patients with HCV infection.
After completing this activity, the participant should be better able to:
Release Date: December 30, 2015
Expiration Date: December 30, 2016
Estimated time to complete this program: 1 hour, 30 minutes
Media: Internet
| Nezam H. Afdhal, MD | |
|---|---|
 |
Professor of Medicine Harvard School of Medicine Chief of Hepatology, Director of Liver Center Beth Israel Deaconess Medical Center Boston, Massachusetts |
| Mark Sulkowski, MD | |
|---|---|
|
Professor of Medicine and Medical Director Viral Hepatitis Center Johns Hopkins University School of Medicine Baltimore, Maryland |
| Paul Kwo, MD | |
|---|---|
 |
Professor of Medicine Medical Director, Liver Transplantation Division of Gastroenterology and Hepatology Indiana University School of Medicine Indianapolis, Indiana |
| Graham R. Foster, FRCP, PhD | |
|---|---|
 |
Professor of Hepatology The Liver Unit Consultant Hepatologist Queen Mary University of London London, United Kingdom |
| Norah A. Terrault, MD, MPH | |
|---|---|
 |
Professor of Medicine & Surgery |
| Rafael Esteban, MD | |
|---|---|
 |
Head, Internal Medicine and Liver Unit Hospital Universitario Val d’Hebron Professor of Medicine Universidad Autonoma de Barcelona Barcelona, Spain |
| Stefan Zeuzem, MD | |
|---|---|
|
Professor of Medicine and Chief |
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and ViralEd, Inc. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.
The Postgraduate Institute for Medicine designates this The Postgraduate Institute for Medicine designates this live activity for a maximum of 2.00 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to provideing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commerical interest.
Nezam Afdhal, MD
Graham R. Foster, FRCP, PhD
Paul Kwo, MD
Norah A. Terrault, MD, MPH
Stefan Zeuzem, MD
Mark Sulkowski, MD
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:
The following PIM staff serve as clinical content reviewers and/or participate in planning CME/CE activities in a manner that may affect content:, Judi Smelker-Mitchek, RN, BSN; Trace Hutchison, PharmD; Samantha Mattiucci, PharmD, CCMEP; Jan Shultz, RN, MSN, CCMEP and Patricia Staples, MSN, NP-C, CCRN hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interests related to the content of this CME/CE activity of any amount during the past 12 months.
There are no fees for participating and receiving CME credit for this activity. During the period, December 30, 2015 through December 30, 2016, participants must read the learning objectives and faculty disclosures and study the educational activity.
PIM supports Green CME by offering your Request for Credit online. If you wish to received acknowledgment of completing this activity, please complete the post-test and evaluation on www.cmeuniveristy.com. On the navigation menu, click on "Find Post-test/Evaluation by Course" and search by course ID 10988. Upon registering and successfully completing the post-test with a score of 70% or better and the activity evaluation, your certificate will be made available immediately. Processing credit requests online will reduce the amount of paper used by nearly 100,000 sheets per year.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Presented for attendees of the 66th AASLD Annual Meeting. This event/function is jointly provided by ViralEd, Inc. and Postgraduate Institute for Medicine and supported by an independent educational grant from Merck & Co. This is not an official function/event of the American Association for the Study of Liver Diseases.
